0000000000658393

AUTHOR

Catherine Loustalot

showing 8 related works from this author

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

2013

Background: The aim of this study was to assess long-term quality of life (QoL) over a period of 6 years in women with breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. Methods: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The longitudinal effect of surgical modalities on QoL was assessed with a mixed model analysis of variance for repeated measurements. Results: Five hundred and eighteen BC patients were initially include…

Cancer Researchmedicine.medical_specialtyTime FactorsHealth StatusBreast surgerymedicine.medical_treatmentSentinel lymph nodeBreast Neoplasmsbreast cancerBreast cancerQuality of lifeSurveys and QuestionnairesBody ImageHumansMedicineAgedSentinel Lymph Node Biopsybusiness.industryCarcinoma Ductal BreastAxillary Lymph Node DissectionCancerMiddle AgedSentinel nodemedicine.diseasehumanitiesSurgeryLymphedemaquality of lifeOncologyClinical StudyLymph Node ExcisionFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesBritish Journal of Cancer
researchProduct

Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer

2011

Abstract Purpose. This prospective multicenter study explored different definitions of time to deterioration (TTD) in quality of life (QoL) scores, according to different cutoffs of the minimal clinically important difference (MCID) as a modality for longitudinal QoL assessment in breast cancer patients. Methods. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and BR-23 before surgery, after surgery, and 6 and 12 months later. The global health score, arm symptoms score (BRAS), and breast symptoms score were analyzed. For a given baseline score, QoL was considered to have deteriorated if this score decreased by ≥5 point…

Cancer Researchmedicine.medical_specialtyMultivariate analysisSentinel lymph node[SDV.CAN]Life Sciences [q-bio]/CancerBreast Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/CancerCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeInternal medicinemedicineHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overbusiness.industryProportional hazards modelSentinel Lymph Node BiopsyMinimal clinically important differenceMiddle Agedmedicine.diseasehumanities3. Good healthSurgeryOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisQuality of LifeLymph Node ExcisionFemalebusinessCohort study
researchProduct

A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissec…

2009

Background: This prospective multicenter study assessed and compared the impact of different surgical procedures on quality of life (QoL) in breast cancer patients. Patients and methods: The EORTC QLQ-C30 and the EORTC QLQ-BR-23 questionnaires were used to assess global health status (GHS), arm (BRAS) and breast (BRBS) symptom scales, before surgery, just after surgery and 6 and 12 months later. The Kruskal–Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. Results: Before surgery, GHS (P = 0.7807) and BRAS (P = 0.7688) QoL scores…

medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancerQuality of lifemedicineHumansProspective Studiesbusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionHematologySentinel nodeMiddle Agedmedicine.diseasehumanitiesSurgeryOncologyLymphatic MetastasisQuality of LifeLymph Node ExcisionLymphadenectomyFemaleBreast diseaseLymph NodesbusinessCohort studyAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

2021

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analy…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyReceptor ErbB-2Lobular carcinomaDNA Mutational AnalysisTriple Negative Breast NeoplasmsArticlePathology and Forensic Medicine03 medical and health sciencesBasal (phylogenetics)Phosphatidylinositol 3-Kinases0302 clinical medicineBreast cancerInternal medicinemedicineCarcinomaHumansskin and connective tissue diseasesSurvival analysisAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseAndrogen receptorbody regionsCarcinoma Lobular030104 developmental biologyPleomorphism (cytology)Receptors EstrogenReceptors Androgen030220 oncology & carcinogenesisInvasive lobular carcinomaMutationFemalebusinessModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes

2012

BACKGROUND The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the first course of neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS One hundred and fifteen women with newly diagnosed, large or locally advanced breast cancer undergoing NAC were included. Estrogen receptor (ER), progesterone receptor (PR) and HER2 status were used to define three major tumor subtypes: triple negative (TN) (ER-/PR-/HER2-), luminal (ER+ and/or PR+; HER2-) and HER2 positive (HER2+). Using Fluorine-18 fluorodeoxyglucose positron emission tomography, the tumoral standard uptake value (SUV) maximal index was m…

CA15-3Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorStandardized uptake valueAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicineProgesterone receptormedicineHumansskin and connective tissue diseasesPathologicalComputingMilieux_MISCELLANEOUSChemotherapybusiness.industryHematologyMetabolismmedicine.disease3. Good healthOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPositron-Emission TomographyFemalebusinessTomography X-Ray Computed
researchProduct

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene

2013

International audience; Fanconi anaemia (FA) is characterized by progressive bone marrow failure, congenital anomalies, and predisposition to malignancy. In a minority of cases, FA results from biallelic FANCD1/BRCA2 mutations that are associated with early-onset leukaemia and solid tumours. Here, we describe the clinical and molecular features of a remarkable family presenting with multiple primary colorectal cancers (CRCs) without detectable mutations in genes involved in the Mendelian predisposition to CRCs. We unexpectedly identified, despite the absence of clinical cardinal features of FA, a biallelic mutation of the FANCD1/BRCA2 corresponding to a frameshift alteration (c.1845_1846del…

AdultBiallelic MutationRNA Splicing[SDV]Life Sciences [q-bio]DNA Mutational AnalysisBiologymedicine.disease_causeArticleFrameshift mutationGeneticsmedicineHumansMissense mutationAge of OnsetGeneAllelesGenetics (clinical)BRCA2 ProteinGeneticsMutationPoint mutationComputational BiologyChromosome BreakageBRCA2 ProteinPedigree3. Good healthAmino Acid SubstitutionMutationFemaleRNA Splice SitesChromosome breakageColorectal NeoplasmsEuropean Journal of Human Genetics
researchProduct

Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines a…

2021

Summary Purpose In the ACOSOG Z0011 trial, patients with primary breast cancer and 1–2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The ai…

AdultCancer Researchmedicine.medical_specialtyLymphovascular invasionmedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancermedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyMastectomySocieties MedicalAgedAged 80 and overbusiness.industryAxillary Lymph Node DissectionCancerHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUnited StatesOncologyLymphatic MetastasisAxillaPractice Guidelines as TopicLymph Node ExcisionFemaleGuideline AdherenceRadiologySentinel Lymph NodebusinessMastectomyBulletin du Cancer
researchProduct

The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulatio…

2004

International audience; 1. In order to compare the beta(2)- and beta(3)-adrenoceptor (beta-AR) desensitisation process in human near-term myometrium, we examined the influence of a pretreatment of myometrial strips with either a beta(2)- or a beta(3)-AR agonist (salbutamol or SR 59119A, respectively, both at 10 microm, for 5 and 15 h) on the relaxation and the cyclic adenosine monophosphate (cAMP) production induced by these agonists. 2. To assess some of the mechanisms potentially implicated in the beta-AR desensitisation process, we studied the influence of such treatment on the number of beta(2)- and beta(3)-AR binding sites, the beta(2)- and beta(3)-AR transcripts expression and the pho…

MESH : Receptors Adrenergic beta-3MESH : Adrenergic beta-AgonistsMESH : Receptors Adrenergic beta-2Adrenergic beta-3 Receptor AgonistsMESH : Analysis of VarianceMESH : Dose-Response Relationship DrugMESH: Adrenergic beta-Agonists[SDV.BC]Life Sciences [q-bio]/Cellular BiologyIn Vitro TechniquesMESH: Dose-Response Relationship DrugMESH: PregnancyPregnancyMESH: Analysis of VarianceHumansMESH: Protein BindingAlbuterolMESH : FemaleMESH : AlbuterolAdrenergic beta-2 Receptor Agonists[SDV.BC] Life Sciences [q-bio]/Cellular BiologyAnalysis of VarianceMESH: HumansDose-Response Relationship Drug[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH : MyometriumMESH: AlbuterolMESH : HumansMESH : Protein BindingAdrenergic beta-AgonistsMESH : PregnancyReceptors Adrenergic beta-3PapersMyometriumMESH: MyometriumFemaleReceptors Adrenergic beta-2MESH: Receptors Adrenergic beta-3MESH: Receptors Adrenergic beta-2MESH: FemaleProtein Binding
researchProduct